Condition
Crohn's disease news across medications, symptoms, tests, procedures, complications, research, access, and daily life.
Page 9 of 18 · 826 articles
Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and AI and data science. The original article is from frontiersin.org.
People with Crohn’s often have other inflammatory or immune-related conditions. Knowing these links can help patients and clinicians watch for symptoms that might need evaluation or treatment.
Knowing the range of Crohn’s symptoms helps you recognize when to seek care, track disease patterns, and explain concerns to your clinician. The article highlights location-based differences and serious complications...
Based on the title and source metadata, this appears to be a patient education related to Crohn's disease, Inflammatory bowel disease, and Medications. The original article is from msn.com.
Based on the title and source metadata, this appears to be a patient education related to Crohn's disease and Community and awareness. The original article is from msn.com.
Cure8 found this source from hmpgloballearningnetwork.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Tests and monitoring. Open the original article...
Personal stories raise awareness about how Crohn’s disease affects patients and families, and fundraising helps charities that support research and services. The article may resonate with people coping with surgery,...
Patients with IBD or new symptoms should understand that Crohn’s disease and ulcerative colitis can look very similar but affect different parts of the gut and may require different treatments. Accurate diagnosis matters...
If approved, TREMFYA (guselkumab) could become an additional IL‑23 inhibitor option for adults with moderate‑to‑severe Crohn’s disease, including both IV and SC induction dosing. That may affect treatment choices for...
A CHMP recommendation is a major regulatory step toward EU approval — that could mean a new biologic option (guselkumab/Tremfya) for adults with moderate–severe Crohn’s disease, including people who haven’t responded to...
A CHMP positive opinion means guselkumab (Tremfya) could become an approved treatment option for adults with moderately to severely active Crohn’s disease in the EU, offering both IV and SC induction routes. This could...
Cure8 found this source from phl17.com, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease, Crohn's disease, and Community and awareness. Open the original article for the full...
Women with Crohn’s may have additional or different symptoms (period changes, painful sex, fertility concerns, bone and iron problems) that can affect daily life and long-term health. Recognizing these issues helps guide...
Patients considering switching biologics or clinicians choosing a second‑line therapy may care because the study suggests ustekinumab had better long‑term persistence and improving remission rates compared with anti‑TNF...
Based on the title and source metadata, this appears to be a regulatory update related to Crohn's disease, Inflammatory bowel disease, and Guselkumab. The original article is from uk.finance.yahoo.com.
You can have active intestinal inflammation even without clear symptoms; early monitoring and tailored treatment aim to prevent complications and preserve quality of life.
Based on the title and source metadata, this appears to be a biomarker study related to Crohn's disease, Ulcerative colitis, and Inflammatory bowel disease. The original article is from msn.com.
This roundup highlights many drugs and trials in development for Crohn’s disease, including late‑stage studies of biologics and newer oral agents — information that could affect future treatment options. Patients on...
Cure8 found this source from medpagetoday.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. Open the original article for...
Cure8 found this source from medpagetoday.com, but the page could not be read reliably yet. It is tagged for Crohn's disease and Research and clinical trials. Open the original article for the full details.
IBD can present in uncommon ways in children — including as an intraluminal abdominal mass that mimics tumors. Early recognition avoids misdiagnosis and guides appropriate surgical and medical follow-up.
Based on the title and source metadata, this appears to be a clinical trial phase 3 related to Crohn's disease, Inflammatory bowel disease, and Guselkumab. The original article is from firstwordpharma.com.
Based on the title and source metadata, this appears to be a fda approval related to Crohn's disease, Inflammatory bowel disease, and Mirikizumab. The original article is from specialtypharmacycontinuum.com.
If you have moderate to severe Crohn’s disease, this study suggests some patients who don’t respond to initial risankizumab induction may still benefit from a longer induction period, including improved symptoms and...
Based on the title and source metadata, this appears to be a patient education related to Crohn's disease, Inflammatory bowel disease, and Medications. The original article is from webmd.com.
Chronic inflammation in Crohn’s, especially when the colon is affected, raises colorectal cancer risk over time. Knowing risk factors and recommended screening helps people with Crohn’s get earlier detection and...
An FDA approval means guselkumab (Tremfya) is now an approved treatment option for adults with moderate-to-severe Crohn’s disease, including a unique option for fully subcutaneous induction. This may expand choices for...
Cure8 found this source from hmpgloballearningnetwork.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Guselkumab, and IL-23 inhibitor. Open the original article for the full details.
Cure8 found this source from wyomingnews.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Guselkumab. Open the original article for the full details.
This large observational study suggests that diets high in nutrient-dense plant foods (not processed plant products) were linked to lower risk of developing IBD and to fewer IBD-related surgeries. People with IBD often...
This report outlines which drugs and companies are shaping Crohn’s disease treatment options and predicts market shifts that may affect treatment availability, costs, and future therapy choices.
A biomarker that appears before inflammation could help detect Crohn’s disease earlier or predict relapses. Understanding early immune changes may point to new preventive strategies rather than only treating inflammation...
This study provides real‑world data on upadacitinib’s ability to produce clinical and endoscopic remission in people with Crohn’s disease, information that can help patients and clinicians weigh treatment options.
The study identifies a possible early immune-cell change that may trigger Crohn’s disease-like inflammation and suggests a potential biomarker (loss of γδ IELs) and therapeutic direction. For people with IBD, this could...
Cure8 found this source from medindia.net, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. Open the original article for the...
This study suggests whey protein intake may influence gut viruses and bacteria in ways that could lower Crohn’s disease risk and reduce inflammation—an intersection of diet and microbiome research that could point to...
The findings point to an immune-cell change that may happen before Crohn’s symptoms appear, which could help predict relapse or guide future therapies. That could eventually affect monitoring or new treatment strategies...
This study identifies a specific immune cell (γδ intraepithelial lymphocytes) that may fail before Crohn’s disease appears, which could help researchers develop early biomarkers or new therapies to prevent inflammation.
Based on the title and source metadata, this appears to be a basic science related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from msn.com.
This FDA approval adds another biologic option (an IL-23 inhibitor) for adults with moderate-to-severe Crohn’s disease, including both self-administered subcutaneous dosing and an IV induction route. New options may...
Regulators asked Roche to provide early-phase Crohn’s disease data before advancing review of a Phase 3 protocol for RO7790121, a monoclonal antibody targeting TL1A—an emerging target in IBD.
Research that maps neutrophil behavior in children with Crohn’s could reveal biological mechanisms and biomarkers relevant to disease progression or treatment response. Understanding neutrophil roles helps scientists...
Based on the title and source metadata, this appears to be a fda approval related to Crohn's disease, Inflammatory bowel disease, and Guselkumab. The original article is from msn.com.
Cure8 found this source from science.org, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. Open the original article for the...
Cure8 could only read part of this source from endpts.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Guselkumab.
Cure8 found this source from medpagetoday.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Guselkumab. Open the original article for the full details.
Cure8 found this source from onlinelibrary.wiley.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Adalimumab, and Anti-TNF. Open the original article for the full details.
Cure8 could only read part of this source from managedhealthcareexecutive.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and...
